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Abstract Metabolic alterations are a key player in-
volved in the onset of Alzheimer disease pathophysi-
ology and, in this review, we focus on diet, metabolic
rate, and neuronal size differences that have all been
shown to play etiological and pathological roles in
Alzheimer disease. Specifically, one of the earliest
manifestations of brain metabolic depression in these
patients is a sustained high caloric intake meaning that
general diet is an important factor to take in account.
Moreover, atrophy in the vasculature and a reduced
glucose transporter activity for the vessels is also a
common feature in Alzheimer disease. Finally, the
overall size of neurons is larger in cases of Alzheimer
disease than that of age-matched controls and, in indi-
viduals with Alzheimer disease, neuronal size inversely
correlates with disease duration and positively associ-
ates with oxidative stress. Overall, clarifying cellular
and molecular manifestations involved in metabolic
alterations may contribute to a better understanding of
early Alzheimer disease pathophysiology.
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Brief introduction
There are a great number of hypotheses concerning
Alzheimer disease (AD). The predominant theories
focus on specific abnormalities that are used in the
diagnosis of disease such as production of amyloid-b
(Ab42) [1–3] and s phosphorylation [4, 5]. As previ-
ously discussed [6–8], the lesions of disease should be
viewed as surrogates or consequences of the disease
process rather than pathogenic. With this in mind, we
previously found that oxidative stress precedes both
pathologies by decades in both sporadic and familial
AD [9–14]. Key factors contributing to oxidative stress
in AD are slowly being elucidated with redox metal
Special issue dedicated to John P. Blass.
Gemma Casadesus and Paula I. Moreira contributed equally to
this paper. Aspects of this paper were previously presented in
Neurochemical Research 28, 1549–1552, 2003 and the Journal of
Alzheimer’s Disease 1, 203–206, 1999 and were used here with
permission.
G. Casadesus
Department of Neuroscience, Case Western Reserve
University, Cleveland, OH, USA
P. I. Moreira
Center for Neuroscience and Cell Biology of Coimbra,
University of Coimbra, Coimbra, Portugal
A. Nunomura
Department of Psychiatry and Neurology, Asahikawa
Medical College, Asahikawa, Japan
S. L. Siedlak  M. A. Smith  G. Perry
Department of Pathology, Case Western Reserve
University, Cleveland, OH, USA
W. Bligh-Glover  E. Balraj
Cuyahoga County Coroner’s Office, 11001 Cedar Avenue,
Cleveland, OH, USA
G. Petot
Department of Nutrition, Case Western Reserve University,
Cleveland, OH, USA
G. Perry (&)
College of Sciences, University of Texas at San Antonio,
6900 North Loop 1604 West, San Antonio, TX 78249-0661,
USA
e-mail: george.perry@utsa.edu
123
Neurochem Res (2007) 32:717–722
DOI 10.1007/s11064-007-9296-y
ions [15, 16], mitochondria [17], and mitotic alterations
being the focus of our groups. Bringing all these
aspects together, this review explores the interplay
between metabolic factors, which have been implicated
in the progression and pathogenesis of AD.
Brain metabolism in Alzheimer disease
John Blass and colleagues presented some of the ear-
liest, and many would say best, biochemical studies of
AD highlighting deficiencies in key enzymes of energy
metabolism, in particular a-ketoglutarate and pyruvate
dehydrogenase [18–20]. Reduced enzymatic activities
were not only noted in brain of AD cases but also in
other tissues and even in fibroblasts cultured from AD
patients. Consistent with this, metabolic imaging stud-
ies show reduced glucose utilization as early as, maybe
even preceding, the onset of clinical symptoms, in
genetically predisposed individuals [21]. Indeed, re-
duced glucose metabolic rate in the temporoparietal
and posterior cingulate cortex is evident in both AD
and in subjects with mild cognitive impairment (MCI)
[22]. That such metabolic alterations are key contrib-
utors to the pathogenesis of AD is highlighted by
studies on patients with at least one e4 allele of apoli-
poprotein E (ApoE), where reduced glucose metabo-
lism levels in limbic and associative areas of the brain
supports the notion that ApoE4 carriers are more
prone to develop metabolic deficiency and AD at an
early age [23]. Moreover, such changes are evident
even in young and presymptomatic ApoE4 carriers
[24], indicating a possible causal route of AD in ApoE4
individuals.
The vasculature, the major metabolic exchange
surface of the brain, is consistently atrophied in AD
[25] and, like other brain compartments, shows re-
duced glucose transport [26]. These findings emphasize
the multiplicity of causes and effects of lowered met-
abolic function such that baseline glucose metabolism
and medial temporal lobe brain volumes are predictive
of cognitive decline in normal older people [27].
Notably, amyloid-b interacts with insulin receptors and
glucose transporters [28] and there are emerging par-
allels being drawn between diabetes and AD [29–32].
Indeed, amyloid formation in the pancreas is associ-
ated with b-cell loss in Type 2 diabetes [33] and a
disturbance in the control of neuronal glucose metab-
olism, consequent to impaired insulin signaling atro-
phy, resembles the pathophysiology of Type-2 diabetes
in non-neuronal tissue [34]. Seen together, these find-
ings make a case for a metabolic contribution to the
pathogenesis of AD.
Dietary intake and Alzheimer disease
The cerebral metabolic alterations in AD patients
mentioned above are likely reflective or consequential
to a number of factors including dietary intake. In this
regard, a high caloric diet seemingly predates onset of
disease [35–37] (Table 1). Moreover, patients who la-
ter develop AD show reduced intake of key antioxi-
dant nutrients throughout life (Table 2).
Lipid transport is a known function of apolipopro-
tein E (ApoE), whose genotype has been established
as a risk factor for AD [38]. Proper functioning of this
protein is critical to membrane formation and the
repair of nervous system injuries. Notably, a high fat
diet is a risk factor in the development of AD [39, 40].
Table 1 Caloric intake of AD and control cases during three
periods of adult life, ages 20–39 years, 40–59 years and 60+ years
Age Period Mean Median S.D.
20‘S and 30‘S
AD (n=78) 2115 2051 715
Controls (n=212) 2092 2100 641
40‘S and 50‘S
AD (n=108) 2152 2089 710
Controls (n=225) 2076 2125 648
60+
AD (n=84) 2148 2076 702
Controls (n=232) 1704 1658 487
Reprinted from J Alzheimer’s Disease 1:203–206, 1999 with
permission from IOS Press
Table 2 Dietary patterns throughout life indicate significantly
greater consumption by controls than AD cases of vitamins A, C
and carotenoids, and more servings per day of foods that contain
these nutrients (37)
Nutrients per 1000
kilocalories
AD
Cases
n=104
Controls
n=223
P Value
Vitamin A (RE) 855 983 .001
a Carotene (mcg) 294 389 <.001
b Carotene (mcg) 1921 2370 .003
Pro-ACarotene (mcg) 2231 2809 .001
Lutein (mcg) 972 1214 .015
Lycopene (mcg) 666 927 <.001
Vitamin C (mg) 74.6 86.7 .007
Vitamin E (a TE) 5.6 5.9 NS
Servings per day
Yollow green vegetables 2.0 2.3 .022
Vitamin C fruit,
vegetables
2.4 2.6 NS
These data strongly support the notion that free radical scav-
engers, here dietary antioxidants, delay or prevent the onset of
AD. Reprinted from J Alzheimer’s Disease 1:203–206, 1999 with
permission from IOS Press
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Interestingly, diet can also influence pathological
markers of AD. In this regard, and associated with
insulin function/resistance and metabolism, recent data
indicates that Insulin-degrading enzyme (IDE), one
protein with a key role in degrading amyloid-b mono-
mer [41], is decreased in AD [42]. Providing interplay
between the aforementioned high fat diets contribute
to insulin resistance and lower IDE and, in animal
models of AD, lead to increased amyloid deposition
[43]. Altogether, these data indicate a key role that
dietary influences may play in maintaining healthy
brain structure and function.
Neuronal size and Alzheimer disease
To clarify the relationship between brain metabolic
activity, neuronal size, and the evolution of AD, we
found, in a study of oxidative damage in AD and
normal aging, a strong inverse relationship between
neuronal oxidative damage (8-hydroxyguanosine, a
marker of nucleic acid oxidation) and neuronal size
among cases of AD but not controls (Fig. 1). Addi-
tionally, we showed that, in AD cases, neuronal size is
inversely correlated with the duration of the disease
(Fig. 2). Previous studies found that during the pro-
gression of the disease there is a significant decrease in
the size of neurons in AD when compared to controls
[12, 35] and our data (Fig. 2) would tend to support
this. However, while the differences in neuron size are
highly correlated with oxidative damage and duration
of disease among the AD cases, the increase in size is
not statistically different from control cases. An alter-
native and more provocative possibility for this dis-
crepancy could be explained by an antioxidant role of
amyloid-b [8]. Given that amyloid-b can serve an
antioxidant function, one possibility could be that
amyloid-b appears as a protective mechanism in a
brain inherently vulnerable to oxidative stress, which
initially normalizes neuronal function and size and
then through progressive accumulation alters cellular
structures enough to cause neuronal shrinkage and
death, as other reports have shown [6–14]. Nonethe-
less, it is intriguing that large neurons in AD appear
most vulnerable and supporting this, we also observed
that neurons from cases of Down syndrome are sig-
nificantly larger than control cases (Fig. 3). Down
syndrome parallels AD in lesion formation, markers of
oxidative damage and most of the other changes of
AD, yet these changes occur decades earlier [44]. In
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Fig. 1 In cases of AD, neuron size is directly correlated with
increased levels of 8-hydroxyguanosine (8OHG) (P = 0.002),
while control cases do not display this relationship (P = 0.18).
Reprinted from Neurochem Res 28:1549–1552, 2003 with kind
permission of Springer Science and Business Media
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Fig. 2 In cases of AD, neuron size is inversely correlated with
the duration of the disease (P = 0.03). This buttresses our
previous finding that neuron size decreases with increasing levels
of amyloid. Reprinted from Neurochem Res 28:1549–1552, 2003
with kind permission of Springer Science and Business Media
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Fig. 3 Neuron size was measured in the same area of the
hippocampus in AD (n = 22), Down syndrome (n = 22) and
control (n = 64) cases. Cases of Down syndrome had significantly
larger neurons than the control cases (P = 0.00006). While the
average neuron size for the AD cases was higher than the control
cases, the difference did not reach significance (P = 0.076;
Student’s t-test). Reprinted from Neurochem Res 28:1549–1552,
2003 with kind permission of Springer Science and Business
Media
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addition, Down syndrome cases also experience neu-
ronal loss and have similar genetic risk factors [35].
To determine the relationship between neuronal
size, AD, and ApoE genotype, we determined the
ApoE genotype of the control cases to identify those at
risk of AD. Control cases (ages 42–85 years) with at
least one ApoE4 allele had a cross sectional area sig-
nificantly larger compared to other controls lacking
ApoE4. In contrast, young controls (ages 20–40 years)
show no correlation between neuronal size and ApoE
genotype. These findings further suggest that the
ApoE4 allele may play a role during aging and disease
progression that influences neuron size. As such, one
possibility is that the alteration of lipid or axonal
transport of ApoE4 carriers may be a cause of the
accumulation of organelles [45] within neurons early in
the disease, leading to a neuronal enlargement and
then to neuronal shrinkage and death during the pro-
gression of AD. Supporting this idea, while AD is
associated with a significantly reduced size of the Golgi
apparatus, individuals with mild cognitive impairment
(MCI) show substantially increased size [46]. Another
possibility is that, in order to compensate for metabolic
dysfunction produced by, for example, ApoE4 status,
organelles associated with metabolism undergo a
compensatory enlargement that may then lead to fur-
ther damage and subsequent shrinkage and death of
the neuron in more advanced stages of AD.
As a side note, related to ApoE genotype, an
interesting trend was apparent when analyzing young
controls. Out of 13 cases under the age of 32, six car-
ried an ApoE2 allele. Most of the genetic studies in
aging and AD focus on the increase in ApoE4 [47] and
some studies [48–50], but not all [51], have noted that
ApoE2 is protective for AD. We compared our rela-
tively small sample population with published studies
and determined that the frequency of ApoE2 was
much higher than those reported for other control
populations (Table 3). Of note was the fact that our
samples were obtained postmortem and of the 6 cases
carrying an ApoE2 allele, 3 committed suicide and 2
succumbed to violence. In previous studies, the fre-
quency of ApoE2 was increased in cases with psychosis
[24, 52]. Our results fall into this category-perhaps,
ApoE2 genotype is a determinant of susceptibility to
violent death.
Conclusion
While the data presented above do not illustrate a
causal relationship between neuronal size and AD
development and progression, these changes occur due
to metabolic alterations that appear early in the onset
of the disease. Although there is insufficient data to
know if diet can be protective for neurodegeneration,
or, instead, is a surrogate marker of other lifestyle
patterns promoting general health, it is well known that
proper nutrition and a healthy diet are essential for
maintaining overall good health and, therefore, can be
beneficial to AD patients. These findings allow the
development of new studies focused on the events
associated with the onset of the disease process such as
diet, glucose metabolism, and neuronal size. Those
Table 3 Comparison of previous population studies of ApoE allele frequencies and the cases used in this study
Diagnosis ApoE2 (%) ApoE4 (%) Ratio E4/E2 Age n
Control [53] 7.8 16.9 2.17 76 71
Dementia [53] 2.8 22.2 7.9 80 18
Psychiatric history [53] 12.5 10.7 0.85 71.8 28
Control (Caucasian) [54] 7 12.5 1.79 <30 939
Control (African-American) [54] 14 20 1.43 <30 696
Psychotic (Bipolar) [52] 6.3 15.1 2.39 Mean 33–67 156
Control [52] 6 12.1 2.0 Mean 43.5 91
Schizophrenic [55] 7 7.5 1.07 12–87 54
Dementia [55] 4.6 30.2 6.6 50–95 43
Control [55] 6 15.2 2.5 24–88 33
Control [56] 3.7 19.5 5.7 <18 486
Post-mortem Controla 23 11.5 0.5 <40 13
Post-mortem Controla 0 12.5 >40 8
a Cases obtained from the Cuyahoga County Coroner Office, Cleveland, Ohio
As expected, the populations with dementia display the highest frequency of eE4 and the highest ratio of eE4/E2, 6.6 and 7.9. The 6
control populations, not including our data, have a E4/E2 ratio from 1.43–5.7, with the average frequency of E4 being about 2.5 times
greater than E2. Interestingly, in 2 of the 3 previous studies of ApoE genotype and psychotic behavior, the ratio of E4/E2 is 1.07 and
0.85. Our population study displayed an even greater frequency of ApoE2. Of the 6 cases carrying the ApoE2 allele, 3 committed
suicide. In other words, ApoE2 may be a risk factor for mental illness
720 Neurochem Res (2007) 32:717–722
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studies could be critical for the understanding of basic
mechanisms underlying AD pathophysiology and,
consequently, the development of new therapeutic
strategies.
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